Baird analyst Richard Eastman maintains Donaldson (NYSE:DCI) with a Outperform and lowers the price target from $61 to $59.
Atai Advances R-Ketamine Through Phase 1 Bridging Study, Update And Near-Term Expectations
Clinical-stage biopharma company atai Life Sciences (NASDAQ: ATAI) announced the dosing of the first subject in majority-owned subsidiary Perception Neuroscience’s Phase 1 intravenous-to-subcutaneous